血清和细胞溶质中癌胚抗原（CEA）、糖类抗原125（CA125）及鳞状细胞癌抗原（SCC）水平对可切除非小细胞肺癌生存及复发的预测作用
Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer.
作者信息
Díez M, Torres A, Maestro M L, Ortega M D, Gómez A, Pollán M, Lopez J A, Picardo A, Hernando F, Balibrea J L
机构信息
San Carlos University Hospital, Madrid, Spain.
出版信息
Br J Cancer. 1996 May;73(10):1248-54. doi: 10.1038/bjc.1996.239.
Abstract
Risk of death and risk of recurrence in 108 potentially curable non-small-cell lung cancer patients were analysed with respect of TNM stage, histological type and carcinoembryonic antigen (CEA), CA125 antigen and squamous cell carcinoma antigen (SCC) levels in serum and cytosol. CA125 and CEA levels were closely related to outcome figures. Multivariate analyses indicated that TNM stage and histological type had the best predictive power, but serum and cytosolic CA125 and serum CEA contained additional, independent prognostic information. Predictive information drawn from serum and cytosolic levels proved mutually complementary. We conclude that CA125 and CEA complement TNM classification and histological type for the purpose of quantifying risk of death or recurrence.
摘要
对108例潜在可治愈的非小细胞肺癌患者的死亡风险和复发风险进行了分析，分析内容涉及TNM分期、组织学类型以及血清和细胞溶质中的癌胚抗原（CEA）、CA125抗原和鳞状细胞癌抗原（SCC）水平。CA125和CEA水平与预后数据密切相关。多变量分析表明，TNM分期和组织学类型具有最佳预测能力，但血清和细胞溶质中的CA125以及血清CEA包含额外的独立预后信息。从血清和细胞溶质水平得出的预测信息相互补充。我们得出结论，为了量化死亡或复发风险，CA125和CEA可补充TNM分类和组织学类型。
相似文献
1
Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer.血清和细胞溶质中癌胚抗原（CEA）、糖类抗原125（CA125）及鳞状细胞癌抗原（SCC）水平对可切除非小细胞肺癌生存及复发的预测作用
Br J Cancer. 1996 May;73(10):1248-54. doi: 10.1038/bjc.1996.239.
2
Serum CEA, CA125, and SCC antigens and tumor recurrence in resectable non-small cell lung cancer.血清癌胚抗原、糖类抗原125和鳞状细胞癌抗原与可切除非小细胞肺癌的肿瘤复发
Int J Biol Markers. 1995 Jan-Mar;10(1):5-10. doi: 10.1177/172460089501000102.
3
The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.CA125、CA19.9、NSE 和 SCC 对 I 期非小细胞肺癌的预后价值有限。
Cancer Biomark. 2011;10(3-4):155-62. doi: 10.3233/CBM-2012-0246.
4
Quantitative analysis of carcinoembryonic antigen, squamous cell carcinoma antigen, CA 125, and CA 50 cytosolic content in non-small cell lung cancer.非小细胞肺癌中癌胚抗原、鳞状细胞癌抗原、CA 125和CA 50胞质含量的定量分析。
Cancer. 1994 May 1;73(9):2305-11. doi: 10.1002/1097-0142(19940501)73:9<2305::aid-cncr2820730911>3.0.co;2-d.
5
Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer.癌胚抗原（CEA）和糖类抗原125（CA125）在可切除非小细胞肺癌复发和转移方面的临床价值
Anticancer Res. 2003 Jul-Aug;23(4):3427-32.
6
7
8
9
Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer.七种临床肿瘤标志物在非小细胞肺癌诊断中的评估。
Dis Markers. 2018 Dec 11;2018:9845123. doi: 10.1155/2018/9845123. eCollection 2018.
10
[A clinical study on CA 15-3, CEA, SCC-Ag in patients with squamous cell carcinoma of the lung].[肺癌鳞状细胞癌患者CA 15-3、癌胚抗原、鳞状细胞癌抗原的临床研究]
Rinsho Hoshasen. 1989 Jan;34(1):63-6.
引用本文的文献
1
Multimodal deep learning radiomics model for predicting postoperative progression in solid stage I non-small cell lung cancer.多模态深度学习放射组学模型预测实体期 I 期非小细胞肺癌术后进展。
Cancer Imaging. 2024 Oct 17;24(1):140. doi: 10.1186/s40644-024-00783-8.
2
High circulating activin A plasma levels are associated with tumour stage and poor survival in treatment-naive lung squamous cell cancer patients.在未经治疗的肺鳞状细胞癌患者中，循环血中激活素A的高水平与肿瘤分期及较差的生存率相关。
Transl Oncol. 2025 Jan;51:102153. doi: 10.1016/j.tranon.2024.102153. Epub 2024 Oct 15.
3
Prognostic evaluation of preoperative serum tumor marker-negative cases in non-small cell lung cancer: A retrospective study.术前血清肿瘤标志物阴性的非小细胞肺癌患者预后评估：一项回顾性研究。
Cancer Rep (Hoboken). 2023 Feb;6(2):e1696. doi: 10.1002/cnr2.1696. Epub 2022 Aug 12.
4
The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies With Radiological Features and Histological Types.术前血清肿瘤标志物在非小细胞肺癌中的预后价值因放射学特征和组织学类型而异。
Front Oncol. 2021 Jun 11;11:645159. doi: 10.3389/fonc.2021.645159. eCollection 2021.
5
Combined neat model for the prognosis of postoperative stage III-N2 non-small cell lung cancer.术后 III-N2 期非小细胞肺癌预后的联合整洁模型。
Thorac Cancer. 2020 Sep;11(9):2610-2617. doi: 10.1111/1759-7714.13585. Epub 2020 Jul 29.
6
The preoperative platelet distribution width: A predictive factor of the prognosis in patients with non-small cell lung cancer.术前血小板分布宽度：预测非小细胞肺癌患者预后的指标。
Thorac Cancer. 2020 Apr;11(4):918-927. doi: 10.1111/1759-7714.13340. Epub 2020 Feb 15.
7
Evaluation of the clinical application of multiple tumor marker protein chip in the diagnostic of lung cancer.多种肿瘤标志物蛋白芯片在肺癌诊断中的临床应用评价
J Clin Lab Anal. 2018 Oct;32(8):e22565. doi: 10.1002/jcla.22565. Epub 2018 May 7.
8
Development and validation of a preoperative prognostic index independent of TNM stage in resected non-small cell lung cancer.在可切除的非小细胞肺癌中，建立并验证一个独立于 TNM 分期的术前预后指数。
BMC Pulm Med. 2017 Dec 4;17(1):166. doi: 10.1186/s12890-017-0529-9.
9
Serum dickkopf-1 as a clinical and prognostic factor in non-small cell lung cancer patients with bone metastases.血清Dickkopf-1作为非小细胞肺癌骨转移患者的临床及预后因素
Oncotarget. 2017 Jun 12;8(45):79469-79479. doi: 10.18632/oncotarget.18446. eCollection 2017 Oct 3.
10
The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer.肿瘤标志物的联合检测有助于肺癌的组织学诊断。
Biomed Res Int. 2017;2017:2013989. doi: 10.1155/2017/2013989. Epub 2017 May 18.
本文引用的文献
1
Decline of posttreatment tumor marker levels after therapy of nonsmall cell lung cancer. A useful outcome predictor.非小细胞肺癌治疗后治疗后肿瘤标志物水平的下降。一种有用的预后预测指标。
Cancer. 1995 Apr 1;75(7):1586-93. doi: 10.1002/1097-0142(19950401)75:7<1586::aid-cncr2820750706>3.0.co;2-k.
2
Use of tumor markers in lung cancer.肿瘤标志物在肺癌中的应用。
Hematol Oncol Clin North Am. 1994 Jun;8(3):507-32.
3
Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening.血清肿瘤标志物癌胚抗原（CEA）、糖类抗原50（CA 50）、组织多肽特异性抗原（TATI）及神经元特异性烯醇化酶（NSE）在肺癌筛查中的应用
Cancer. 1993 Mar 15;71(6):1982-8. doi: 10.1002/1097-0142(19930315)71:6<1982::aid-cncr2820710610>3.0.co;2-g.
4
Chemotherapy and radiation for the treatment of non-small-cell lung cancer. A critical review.用于治疗非小细胞肺癌的化疗与放疗。一项批判性综述。
Clin Chest Med. 1993 Mar;14(1):161-71.
5
Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung cancer.血清神经元特异性烯醇化酶、癌胚抗原和CA-50抗原检测在肺癌诊断中的临床应用价值
Eur J Cancer. 1993;29A(2):198-202. doi: 10.1016/0959-8049(93)90174-e.
6
Future directions in the treatment of non-small cell lung cancer.非小细胞肺癌治疗的未来方向
Semin Oncol. 1994 Jun;21(3 Suppl 4):48-62.
7
Quantitative analysis of carcinoembryonic antigen, squamous cell carcinoma antigen, CA 125, and CA 50 cytosolic content in non-small cell lung cancer.非小细胞肺癌中癌胚抗原、鳞状细胞癌抗原、CA 125和CA 50胞质含量的定量分析。
Cancer. 1994 May 1;73(9):2305-11. doi: 10.1002/1097-0142(19940501)73:9<2305::aid-cncr2820730911>3.0.co;2-d.
8
Squamous cell carcinoma antigen (SCC Ag) in the diagnosis and prognosis of lung cancer.鳞状细胞癌抗原（SCC Ag）在肺癌诊断及预后中的应用
Chest. 1994 Mar;105(3):773-6. doi: 10.1378/chest.105.3.773.
9
Prognostic significance of serum CA 125 antigen assay in patients with non-small cell lung cancer.血清CA 125抗原检测在非小细胞肺癌患者中的预后意义。
Cancer. 1994 Mar 1;73(5):1368-76. doi: 10.1002/1097-0142(19940301)73:5<1368::aid-cncr2820730510>3.0.co;2-o.
10
Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung.I期非小细胞肺癌的分子和病理标志物
J Clin Oncol. 1995 May;13(5):1265-79. doi: 10.1200/JCO.1995.13.5.1265.
Zotero 插件